|
Mirdametinib Clinical Trials
7 actively recruiting trials across 6 locations
Also known as: Gomekli, MEK Inhibitor PD0325901, PD 901, PD-0325901
Other1 trial
San Francisco, California1 trial
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
California Pacific Medical Center - Sutter Health
Phase 2
Baltimore, Maryland1 trial
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Johns Hopkins Hospital
Phase 1/2
Bethesda, Maryland1 trial
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center
Phase 1/2
Boston, Massachusetts1 trial
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Dana-Farber - Harvard Cancer Center LAO
Phase 2
Basking Ridge, New Jersey1 trial
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Phase 1/2
Memphis, Tennessee1 trial
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
St. Jude Children's Research Hospital
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.